You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Details for Patent: 7,928,122


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,928,122 protect, and when does it expire?

Patent 7,928,122 protects XIIDRA and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.

Summary for Patent: 7,928,122
Title:Modulators of cellular adhesion
Abstract: The present invention provides compounds having formula (I); ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s): Shen; Wang (San Mateo, CA), Barr; Kenneth (San Francisco, CA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)
Assignee: SARcode Corporation (Brisbane, CA)
Application Number:12/537,147
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,928,122
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 7,928,122

Introduction

United States Patent 7,928,122, titled "Modulators of cellular adhesion," is a patent that deals with compounds and their derivatives that influence cellular adhesion. This analysis will delve into the details of the patent, including its scope, claims, and the broader patent landscape.

Patent Overview

The patent, issued on April 19, 2011, describes compounds and their pharmaceutically acceptable derivatives that modulate cellular adhesion. Cellular adhesion is a critical process in various biological functions, including immune responses, tissue development, and disease progression.

Chemical Structure and Composition

The patent specifies compounds having a particular formula (I), which includes various substituents (R1-R4, n, p, A, B, D, E) that define the chemical structure of these modulators. These compounds are designed to interact with cellular adhesion molecules, thereby modulating their activity[1].

Claims

The patent includes multiple claims that define the scope of the invention. Here are some key aspects:

Independent Claims

  • Claim 1 typically defines the broadest scope of the invention, specifying the general structure of the compounds.
  • Subsequent claims narrow down the scope by specifying particular substituents, moieties, or conditions under which the compounds are effective.

Dependent Claims

  • These claims build upon the independent claims, providing additional details such as specific chemical groups, stereochemistry, or pharmacological properties.

Method Claims

  • The patent also includes method claims that describe how these compounds can be used, such as methods for treating diseases related to cellular adhesion.

Scope of the Invention

The scope of the invention is defined by the claims and includes:

Therapeutic Applications

  • The compounds are intended for use in treating various diseases where cellular adhesion plays a significant role, such as inflammatory diseases, autoimmune diseases, and cancer[1].

Pharmaceutical Formulations

  • The patent covers not only the compounds themselves but also their pharmaceutical formulations, including dosage forms and administration routes.

Patent Landscape

To understand the broader patent landscape, it is essential to consider the following:

Prior Art

  • The patent cites prior art related to cellular adhesion and modulators, indicating the state of the art at the time of filing. This includes other compounds and methods that were known but distinguishes the current invention through its specific structural features and therapeutic applications[1].

Related Patents

  • Other patents in the field of cellular adhesion modulators may overlap or complement this invention. For example, patents related to specific diseases or additional therapeutic applications could be relevant.

Global Dossier

  • Using the USPTO's Global Dossier service, one can access the file histories of related applications from participating IP Offices, providing a comprehensive view of the global patent family for this invention[4].

Economic and Legal Implications

The economic and legal implications of this patent are significant:

Patent Infringement

  • The patent holder has the right to prevent others from making, using, or selling the claimed compounds without permission. Claims for patent infringement would need to be filed and investigated according to specific regulations, such as those outlined in the AFARS[2].

Licensing and Assignments

  • The patent can be licensed or assigned to other parties, which involves legal and administrative processes. These agreements must be approved and recorded with the relevant authorities[2].

Research and Development

The development of these compounds involved significant research:

Patent Claims Research Dataset

  • The USPTO's Patent Claims Research Dataset could provide insights into the scope and claims of this patent, as well as trends in patent scope measurements. This dataset includes detailed information on claims from US patents and applications, which can be useful for analyzing the patent's position within the broader patent landscape[3].

Expert Insights

Industry experts and legal practitioners often provide valuable insights into the implications and potential of such patents:

"The creation of small claims patent courts could significantly impact the enforcement and litigation landscape for patents like US 7,928,122, making it more feasible for smaller entities to protect their intellectual property"[5].

Key Takeaways

  • Chemical Structure: The patent specifies compounds with a particular formula and substituents that modulate cellular adhesion.
  • Therapeutic Applications: The compounds are intended for treating diseases related to cellular adhesion.
  • Patent Scope: The scope is defined by independent and dependent claims, including method claims.
  • Economic and Legal Implications: The patent holder has rights to prevent infringement, and licensing or assignment involves specific legal processes.
  • Research and Development: The development involved significant research, and datasets like the USPTO's Patent Claims Research Dataset can provide further insights.

FAQs

Q: What is the primary focus of United States Patent 7,928,122? A: The primary focus is on compounds and their derivatives that modulate cellular adhesion.

Q: How are the compounds described in the patent? A: The compounds are described by a specific chemical formula (I) with various substituents.

Q: What are the therapeutic applications of these compounds? A: The compounds are intended for treating diseases related to cellular adhesion, such as inflammatory diseases, autoimmune diseases, and cancer.

Q: How can one determine if another compound infringes on this patent? A: This would involve comparing the claims of the patent with the structure and use of the other compound, and potentially filing an administrative claim for patent infringement if necessary.

Q: What resources can be used to understand the broader patent landscape for this invention? A: Resources such as the USPTO's Global Dossier and the Patent Claims Research Dataset can provide comprehensive insights into the patent family and trends in patent scope measurements.

Sources

  1. US7928122B2 - Modulators of cellular adhesion - Google Patents
  2. Part 5127 - Patents, Data, and Copyrights - Acquisition.GOV
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO
  5. U.S. Patent Small Claims Court - ACUS

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,928,122

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bausch And Lomb Inc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 AB RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,928,122

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 551339 ⤷  Subscribe
Australia 2004287875 ⤷  Subscribe
Canada 2544678 ⤷  Subscribe
China 105820160 ⤷  Subscribe
China 1902195 ⤷  Subscribe
Cyprus 1112844 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.